Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of VDJ001 in Idiopathic Multicentric Castleman's Disease
NCT05345522Phase 2Active, not recruiting
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of VDJ-001 in idiopathic multicentric Castleman disease (iMCD), sponsored by Beijing VDJBio Co., Ltd.. Started Apr 2022; status: active, not recruiting.
02
Drugs
VDJ-001
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on NCT05345522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345522.